Login to Your Account



EUROPE NEWS

LONDON – After a barnstorming year for public biotechs across all segments of market capitalization, the sector as a whole is entering a new age of maturity.

ADVANCED THERAPIES INVESTOR DAY

LONDON – The race to deliver a commercial stem cell therapy for treating heart failure is heating up with two products now well advanced in phase III trials. However, the question of whether allogeneic or autologous cells represent the best approach remains unresolved.

ADVANCED THERAPIES INVESTOR DAY

LONDON – The compelling clinical data and widespread interest in chimeric antigen receptor T-cell immunotherapies is infecting regulatory agencies worldwide and they are vying to be first to review one of those products, according to Usman Azam, global head of cell and gene therapies at Novartis AG.

More EUROPE Headlines

Cast Your Vote

Has biotech’s bubble burst?: